From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct

Chronic lymphocytic leukemia (CLL) is an extremely heterogeneous disease. With the advent of oral targeted agents (Tas) treatment CLL has undergone a revolution, which been accompanied by improvement in patient’s survival and quality life. This paradigm shift also affects value prognostic predictive biomarkers models, most them inherited from chemoimmunotherapy era but with different behavior Tas. review discusses: (i) role relevant setting Tas; (ii) validity classic new scoring systems context In addition, critical point view about special emphasis on 11q deletion, novel resistance mutations, TP53 abnormalities, IGHV mutational status, complex karyotype NOTCH1 mutations stated. We go over models early stage such as IPS-E. Finally, we provide overview applicability CLL-IPI for patients treated Tas, well emergence generated data